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ABSTRACT Dityromycin is a peptide antibiotic isolated from the culture broth of
the soil microorganism Streptomyces sp. strain AM-2504. Recent structural studies
have shown that dityromycin targets the ribosomal protein S12 in the 30S ribosomal
subunit, inhibiting translocation. Herein, by using in vitro protein synthesis assays,
we identified the resistance mechanism of the producer strain to the secondary me-
tabolite dityromycin. The results show that the self-resistance mechanism of the
Streptomyces sp. strain AM-2504 is due to a specific modification of the ribosome. In
particular, two amino acid substitutions, located in a highly conserved region of the
S12 protein corresponding to the binding site of the antibiotic, were found. These
mutations cause a substantial loss of affinity of the dityromycin for the 30S ribo-
somal subunit, protecting the producer strain from the toxic effect of the antibiotic.
In addition to providing a detailed description of the first mechanism of self-
resistance based on a mutated ribosomal protein, this work demonstrates that the
molecular determinants of the dityromycin resistance identified in Streptomyces can
be transferred to Escherichia coli ribosomes, where they can trigger the same antibi-
otic resistance mechanism found in the producer strain.
IMPORTANCE The World Health Organization has identified antimicrobial resistance
as a substantial threat to human health. Because of the emergence of pathogenic
bacteria resistant to multiple antibiotics worldwide, there is a need to identify the
mode of action of antibiotics and to unravel the basic mechanisms responsible for
drug resistance. Antibiotic producers’ microorganisms can protect themselves from
the toxic effect of the drug using different strategies; one of the most common in-
volves the modification of the antibiotic’s target site. In this work, we report a de-
tailed analysis of the molecular mechanism, based on protein modification, devised
by the soil microorganism Streptomyces sp. strain AM-2504 to protect itself from the
activity of the peptide antibiotic dityromycin. Furthermore, we demonstrate that this
mechanism can be reproduced in E. coli, thereby eliciting antibiotic resistance in this
human commensal bacterium.
KEYWORDS self-resistance, antibiotic, ribosomal protein S12, translation
The emergence of multidrug-resistant (MDR) bacteria is a growing problem thatrepresents one of the top three threats to global public health worldwide (1–4).
Moreover, it has been estimated that approximately 70% of infection-causing bacteria
are already resistant to at least one antibiotic available in routine clinical practice.
Therefore, all the efforts to provide a detailed molecular picture of a specific resistance
mechanism can contribute positively to improve our understanding of antimicrobial
resistance (AMR) and its dynamics.
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Dityromycin is a cyclic decapeptide antibiotic (Fig. 1A) discovered as a secondary
metabolite produced by Streptomyces sp. strain AM-2504 (5, 6). Its structure is almost
identical to that of GE82832, a translocation inhibitor produced by Streptosporangium
spp. (7–9). Both molecules interact with the same ribosomal site and display the same
mechanism of action, even if they are produced by different microorganisms. The
interaction of dityromycin with the ribosome is peculiar compared to other ribosomal
inhibitors, since it interacts exclusively with the ribosomal protein S12 without a direct
interaction with the 16S rRNA (Fig. 1B and C) (8, 9). Indeed, the binding of dityromycin
to the ribosome is mediated by its interaction with five amino acids at the ribosomal
protein S12, namely, arginine 30, valine 32, arginine 55, histidine 76, and valine 78
(Fig. 1C). Dityromycin inhibits protein synthesis by blocking the translocation of tRNA
through the ribosome, while it has almost no effect on the accommodation of
aminoacyl-tRNA into the P-site or the A-site, in the context of either the 30S ribosomal
subunit or the 70S ribosome (7). Recent studies have shown that dityromycin blocks
the EF-G-dependent translocation of peptidyl tRNA and mRNA without preventing
the ribosomal binding of the elongation factor. In particular, dityromycin hampers the
interaction between domain III of EF-G and protein S12, which is located near the
decoding center of the ribosome, at the interface of two subunits (9, 10).
A strict requirement to ensure that the antibiotic producer cell protects itself when
the active metabolites are produced, accumulated, and released is to possess a
self-resistance mechanism(s) (11). Microorganisms can adopt several strategies to de-
velop self-resistance, such as (i) chemical modification of the target, as in the case of
rRNA methylation or mutation (12, 13); (ii) activation of efflux pumps (14, 15); (iii)
sequestration of the natural product by proteins keeping the active compound in a
bound and inactive state (16, 17); (iv) production of the antibiotic in a prodrug form,
activated through selective cleavage by peptidases found in the periplasmic space, and
subsequently released outside the cell (18, 19); and (v) oxidative inactivation of the
matured prodrug following export (20).
Biochemical and genetic similarities demonstrate that such resistance mechanisms
have prefigured those found subsequently in antibiotic-resistant pathogens, which
have acquired specific genes or gene clusters originally developed by antibiotic pro-
ducers (21).
In this work, we have investigated the self-resistance mechanism developed by
Streptomyces sp. strain AM-2504 toward the antibiotic activity of its natural product
dityromycin. To prevent self-toxicity, this microorganism has evolved a strategy based
on the production of a modified and self-resistant ribosomal protein variant. Our
FIG 1 Interaction of dityromycin with the 30S ribosomal subunit. (A) Chemical structure of the antibiotic dityromycin. (B) Three-dimensional (3D)
structure of the 30S ribosomal subunit (gray) and localization of dityromycin (red) in contact with the ribosomal protein S12 (green). A, P, and
E tRNA binding sites are indicated in blue, yellow, and violet, respectively. (C) Close-up of dityromycin (red) bound to S12 (green) missing the
C-terminal domain. The amino acid residues of S12 involved in the interaction with the antibiotic are also indicated. (Modified from reference 9.)
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approach consisted in analyzing three aspects, namely, identification and biochemical
characterization of the self-resistance mechanism, characterization of the amino acid
residues of the ribosomal protein S12 involved in resistance by the heterologous
expression of site-directed mutants in Escherichia coli, and a phylogenetic analysis of
the dityromycin binding pocket in the ribosomal protein S12.
RESULTS
Identification of the mechanism conferring self-resistance. To determine the
self-resistance mechanism of Streptomyces sp. strain AM-2504 to dityromycin, we set up
a simple experiment evaluating whether the resistance mechanism relied on possible
modifications/secretion of the drug (prodrug or efflux pumps) or was based on
mutations/methylations/modifications of the target.
A translational test programmed with poly(U) was used to compare cell extracts
prepared from either E. coli (S30E.coli) or Streptomyces sp. strain AM-2504 cells (S30Str) in
the presence or absence of the antibiotic. Dityromycin, an antibiotic targeting the
translation elongation phase, completely inhibited protein synthesis with S30E.coli at
concentrations ranging between 1 and 10 M, whereas it did not show any effect on
the poly(U) translation carried out with S30Str (Fig. 2A). The lack of inhibition with the
S30Str extract clearly excluded prodrug or efflux pumps as a possible self-resistance
mechanism.
To test whether this self-resistance mechanism was caused by protective mutations
in the ribosomes or by an enzymatic activity able to modify/deactivate the antibiotic,
70S ribosomes were separated by ultracentrifugation from the post-ribosomal super-
natant (S100) and the fractions were tested by crossed in vitro poly(U) translation
assays. In particular, the effect of dityromycin on Streptomyces 70S ribosomes (70SStr)
was assayed in the presence of E. coli S100 (S100E.coli). Vice versa, Streptomyces S100
extract (S100Str) was tested with E. coli 70S ribosomes (70SE.coli). The results of this
experiment (Fig. 2B) show that the reaction mixtures consisting of S100Str plus 70SE.coli
and S100E.coli plus 70SE.coli were totally inhibited by dityromycin, whereas those formed
by S100E.coli plus 70SStr and S100Str plus 70SStr were not. These results strongly indicate
that the modifications causing the self-resistance of the producer strain lie on the
ribosome.
Since the target of dityromycin is the ribosomal protein S12 (9), 30S ribosomal
subunits from both E. coli and Streptomyces sp. strain AM-2504 were purified. Increasing
concentrations of these isolated particles were used in a pulldown assay conducted in
the presence of a fixed concentration of the antibiotic. After ultracentrifugation at
300,000 g, the supernatants were tested in a translational system based on E. coli cell
extracts programmed with poly(U) to detect the residual presence of unbound dityro-
FIG 2 Identification of the self-resistance mechanism. (A and B) Effects of increasing concentration of dityromycin on poly(U) in vitro translation
based on S30 cell extract of E. coli (red) or Streptomyces sp. strain AM-2504 (black) (A) or crisscrossed assays using post-ribosomal supernatant
(S100) and 70S ribosomes of Streptomyces sp. strain AM-2504 or of E. coli (B). Streptomyces 70S incubated with E. coli S100 or Streptomyces S100
is indicated in blue or black, respectively. E. coli 70S incubated with either E. coli S100 or Streptomyces S100 is indicated in red or green,
respectively. (C) Residual translation inhibition activity of the supernatants obtained from ultracentrifugation of 30S ribosomes preincubated with
dityromycin. After centrifugation of increasing amounts of E. coli 30S (black) and Streptomyces sp. strain AM-2504 30S (red), the residual inhibition
activity of the supernatants was determined in a poly(U) translation test (further details are provided in Materials and Methods).
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mycin (see Materials and Methods). As reported in Fig. 2C, the supernatant resulting
from the pulldown of E. coli 30S subunits incubated with dityromycin did not interfere
with poly(Phe) synthesis. Conversely, the supernatant obtained after centrifugation of
Streptomyces 30S subunits incubated with dityromycin inhibited the reaction. This
result indicates that dityromycin is not bound by the Streptomyces 30S subunits and is
not pulled down during ultracentrifugation, even at high concentrations of ribosomes.
In contrast, dityromycin stably interacts with the E. coli 30S subunits and is thus
removed from the supernatant during the centrifugation step (Fig. 2C). In conclusion,
the present results point to a self-resistance mechanism based on a mutation/modifi-
cation residing in the small ribosomal subunit.
Sequencing of the S12 gene reveals three amino acid substitutions in the
dityromycin binding site. As shown in the crystallographic structure of Fig. 1, dityro-
mycin binds the 30S subunit by interacting exclusively with five critical positions of the
ribosomal protein S12, namely, Arg30, Val32, Arg55, His76, and Val78 (Fig. 1C). To clarify
the role played by S12 in reducing the binding affinity of dityromycin to the 30SStr
subunit (Fig. 2), we sequenced the rpsL gene, encoding the S12 protein of Streptomyces
sp. strain AM-2504. In addition, we sequenced the entire genome of the producer
strain, thus obtaining its first annotated draft genome sequence (22). The comparison
of Streptomyces sp. strain AM-2504 genome with the sequences available in the NCBI
genome data bank allowed us to verify that the strain named AM-2504 described in this
study exhibits 98.6% nucleotide identity with Streptomyces kasugaensis. Therefore, it is
conceivable that Streptomyces sp. strain AM-2504 can be classified as S. kasugaensis.
DNA sequence data demonstrate that three out of five amino acids located in the
dityromycin binding site of S12, namely, Val32Thr, Arg55Lys, and Val78Ile, are different
from those found in the model organism E. coli (Fig. 3). These substitutions are likely the
molecular determinants of the self-resistance mechanism to the antibiotic, preventing
dityromycin binding to the ribosome (Fig. 2C).
Expression of the S12 mutant proteins in E. coli confers resistance to dityro-
mycin. To verify whether these mutations are responsible for the self-resistance of the
producer strain, single substitutions at Val32, Arg55, and Val78 were introduced into
the E. coli rpsL gene, and the mutant genes were provided in trans to the E. coli BL21
strain grown in the presence of increasing concentrations of dityromycin. The experi-
mental system was based on gene expression from the high-copy-number plasmid
pET11a, which contained the rpsL gene isolated from E. coli MC4100 carrying the
original mutation Lys42Arg, which confers resistance to the antibiotic streptomycin. As
FIG 3 Sequence of the rpsL gene of Streptomyces sp. strain AM-2504. Nucleotide and amino acid
sequences of ribosomal protein S12 of Streptomyces sp. strain AM-2504. The amino acids involved in the
interaction with the antibiotic in dityromycin-sensitive ribosomes are circled. Amino acids involved in the
self-resistance mechanism are circled in red.
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shown in Fig. 4A, E. coli cells expressing a wild-type copy of S12, in the absence of the
plasmid, are sensitive to streptomycin, but they become resistant once transformed.
Moreover, the presence of either Val32Thr, Arg55Lys or Val78Ile substitutions did not
affect the streptomycin-resistant phenotype. This demonstrates that the ribosomes
effectively incorporate the S12 protein encoded by the plasmid and respond to the
mutant genetic background supplied in trans. Furthermore, the results shown in Fig. 4B
demonstrate that the ribosomal protein S12 carrying the Val32Thr or Arg55Lys substi-
tution confer dityromycin resistance to E. coli, whereas the cells expressing the point
mutation Val78Ile proved to be susceptible to this antibiotic.
DISCUSSION
The growing number of bacterial pathogens uniquely adapted to survive in the
presence of one or more antibiotics is an extremely serious threat to global health. The
term “antibiotic resistome,” a large repertoire of genes that has been originally devel-
oped by bacteria and is currently remodeled by the selective pressure imposed by drug
use/abuse, has been coined to describe the genetic determinants involved in antibiotic
resistance (23, 24).
Resistance to antibiotics is tightly linked to their production, since microorganisms
producing these molecules must protect themselves against their action. In many cases,
mechanisms of self-resistance have been shown to be mechanistically similar to the
ones identified in clinical pathogens (25). Resistance genes are often carried by the
same gene cluster of the antibiotic biosynthetic enzymes, and their expression is
temporally coupled. Indeed, antibiotic producer cells need to express resistance deter-
minants prior to, or concomitantly with, synthesis of the antibiotic molecule (26, 27). In
recent years, the analysis of several genomes suggested that microorganisms produce
only a fraction of the secondary metabolites that they encode, and new approaches
have been used to identify biosynthetic gene clusters whose expression can be
induced. The colocalization of resistance genes and biosynthetic genes in the genomes
FIG 4 Mutations in ribosomal protein S12 confer resistance to dityromycin in E. coli. (A) Determination
of MIC of streptomycin on E. coli BL21(DE3)/pLysS (a) transformed with pET11a-rpslK42R (b) or with
pET11a-rpslK42R carrying the site-directed mutation of the dityromycin binding pocket V32T (c), R55K (d),
or V78I (e). (B) Determination of MIC of dityromycin on E. coli BL21(DE3)/pLysS transformed with
pET11a-rpslK42R (a) or with pET11a-rpslK42R carrying the site-directed mutation of the dityromycin binding
pocket V32T (b), R55K (c), or V78I (d). The streptomycin concentrations were 0, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0,
32.0, 64.0, 128.0, 256.0, and 512.0 g/ml in lanes 1 to 12, respectively. The dityromycin concentrations
were 0, 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25.0, 50.0, 100.0, 200.0, and 400.0 g/ml from lanes 1 to 12,
respectively.
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of underexploited groups of secondary metabolite producers, for example, has been
used in pursuit of new biosynthetic pathways. This genome mining approach, guided
by the search for self-resistant determinants, has been successful for topoisomerase
inhibitors whose biosynthetic gene cluster has been identified by looking for putative
pentapeptide repeat proteins, which are known to confer self-resistance to these
molecules (28).
More than half of the antibiotics currently used inhibit protein synthesis by binding
to the functional centers of the ribosome. Recently, important insights into the mech-
anism of these antibiotics have been obtained by X-ray crystallography and cryo-
electron microscopy (Cryo-EM) analysis, opening the possibility of developing new
molecules by structure-based drug design (29–36).
In this work, we characterized the mechanism of self-resistance of the dityromycin
producer Streptomyces sp. strain AM-2504. Using E. coli and Streptomyces-based in vitro
translation assays in combination with an ultracentrifugation pulldown assay, we
demonstrated that the resistance determinants are localized in the Streptomyces 30S
ribosomal subunit. Since the target of dityromycin is the ribosomal protein S12, we
sequenced the gene coding for Streptomyces S12 and compared it with its E. coli
homolog. Three amino acids in the Streptomyces protein (out of the five involved in the
interaction with the antibiotic) differed from the E. coli protein sequence. Therefore, we
suggest that the molecular basis underlying the self-resistance mechanism could be the
reduced affinity of the antibiotic toward its target due to the amino acid substitutions
on the ribosomal protein S12. To confirm this hypothesis, we introduced the observed
amino acid substitutions into a plasmid-borne copy of E. coli rpsL gene harboring
another mutation conferring resistance to the antibiotic streptomycin. The observed
streptomycin resistance phenotype provides explicit, albeit indirect, evidence that the
plasmid gene encoding ribosomal protein S12 is effectively incorporated into the 30S
subunits. Even though the setup of the assay did not allow strict quantification of the
number of copies of mutant protein incorporated, it showed unequivocally that this
incorporation took place and that plasmid-encoded S12 bearing two specific mutations
in the dityromycin binding site conferred resistance to the antibiotic. The results shown
in Fig. 4B clearly indicate the effects of amino acid replacements at the three key sites
of ribosomal protein S12 involved in the binding of the antibiotic. In particular, at
position 32, the substitution of the nonpolar aliphatic valine with the polar amino acid
threonine interferes with the hydrophobic interaction established with the dityrosine
group of dityromycin according to the crystal structure of the dityromycin-30S com-
plex. It has been pointed out by crystallographic analysis that the arginine at position
55 packs against the N,N-dimethyl valine of the antibiotic (9). Our results strongly
indicate that the replacement of a positively charged side chain, as in the case of lysine,
is not sufficient to maintain the correct structure of the binding site, which presumably
requires the chemical properties of the guanidinium group of arginine. This finding is
consistent with the high specificity demonstrated by the arginine side chain in the
interaction of proteins with their substrates (37, 38). On the other hand, we demon-
strate that the substitution of Val78 with isoleucine does not interfere with the
interaction of dityromycin with S12.
To identify the degree of conservation of the amino acid residues responsible for
dityromycin resistance, we aligned the S12 sequences to 72 Streptomyces spp.
randomly selected from the NCBI database. The alignment shows that, of the three
residues considered, only Ile78 (Val in E. coli) is conserved in all Streptomyces
sequences analyzed. The other two key residues are quite rare, with Thr32 (Val in E.
coli) reported only in 7 out of 72 genomes (Streptomyces antioxidans, S. autoliticus,
S. gilvosporeus, S. iranensis, S. malaysiensis, S. natalensis, and S. violaceusniger) and
Lys55 (Arg in E. coli) in only two strains, S. gilvosporeus and S. natalensis. Therefore,
the results of this comparative analysis show that only 2 of 72 Streptomyces strains
share the same S12 residues conferring resistance to dityromycin as Streptomyces
sp. strain AM-2504 (see Fig. S1 in the supplemental material). When the comparative
analysis was extended to 30 bacterial strains randomly covering all relevant
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branches of the phylogenetic tree, it was found that all selected bacteria display a
valine at position 32, embedded in a stretch of four amino acids (RGVC), which is
highly conserved and it is part of the “core” of a pseudo beta-barrel of S12 (Fig. S2A
and S2B). The other two residues are less conserved, since Lys55 and Ile78 are found
in 4 strains and 11 bacterial strains, respectively.
To our knowledge, the results of this work represent the first example of a self-
resistance mechanism mediated by a ribosomal protein in the producer strain. Resis-
tance mechanisms identified by isolation of single mutations are extremely rare among
ribosomal proteins. Point mutations in rpsL, the gene encoding S12, have been iden-
tified as the key factor conferring streptomycin resistance (39) and at the same time
activate the expression of cryptic antibiotics, like the blue-colored actinorodhin (40, 41).
This intriguing finding, which is the first reported evidence of an effect induced on gene
expression by a point mutation located on a ribosomal protein, is still lacking a detailed
explanation at the molecular level. A few other examples include protein L3, where a
single mutation has been shown to confer resistance to tiamulin, the semisynthetic
derivative of pleuromutiline, reducing its binding affinity for the ribosome and muta-
tions in L16 conferring resistance to the oligosaccharide antimicrobial agents avilamy-
cin (42) and evernimicin (43). In Pasteurella multocida, a bacterium responsible for
zoonotic diseases, a combination of amino acid changes on ribosomal protein S5 (point
mutation at Ser32 and amino acid deletion at Phe33) and a single transversion in helix
34 of 16S rRNA have been identified as the molecular determinants of spectinomycin
resistance (44).
In summary, we can conclude that Streptomyces sp. strain AM-2504 has devel-
oped a successful strategy to protect its own ribosomes from the effect of dityro-
mycin, combining the effects of three amino acid substitutions, which occur as
isolated point mutations in other Actinomyces strains and are compatible with the
structural function of ribosomal protein S12. Although this resistance mechanism
does not fall into the category of antibiotic resistance transfer and spreading, in a
strict sense, the characterization of this strategy at the molecular level adds a new
piece to the complex puzzle underlying the coevolution of antibiotic production
and self-resistance mechanisms.
MATERIALS AND METHODS
Media. ISP2 medium (sporulation agar) consists of 0.4% yeast extract, 0.4% glucose, 1% malt extract,
and 2% agar. T1 medium contains 1% glucose, 2% starch, 0.5% yeast extract, 0.5% peptone, and 0.4%
CaCO3. JM medium consists of 0.1% yeast extract, 0.1% MgCl2 (6H2O), 0.3% Tryptone Soya, and 10%
sucrose. In all cases, the pH of the medium was adjusted to 7.0 prior to autoclaving. Luria-Bertani medium
was used for the growth of Escherichia coli strains utilized for propagation of plasmids and for the
preparation of ribosomes and cell extracts.
Culture conditions of Streptomyces sp. strain AM-2504. For the production and isolation of spores,
Streptomyces sp. strain AM-2504 was grown in ISP2 medium for 7 to 10 days at 28°C. The white aerial
mycelium, consisting of spores, was stripped from the upper layer of the plate using a spatula and
dispersed into 1 ml of sterile water. The spore suspension was filtered through a wad of absorbent
cotton, and the spores were concentrated by centrifugation at 4,000 rpm for 15 min. The spores were
resuspended in 100 l of 20% glycerol and stored at –20°C.
Genomic DNA extraction. Streptomyces spores (20 l) were inoculated in 20 ml of JM medium at
28°C for 18 h with aeration. Cells were collected by centrifugation, and genomic DNA was extracted using
the Invisorb spin plant minikit (Invitek).
DNA amplification and sequence of rpsL from Streptomyces sp. Oligonucleotide primers GSF1 and
GSR1 (Table 1), designed to cover the coding region of the rpsL gene from Streptomyces, were used to
amplify by PCR the target gene using genomic DNA as the template. The DNA sequence of the amplicon,
covering approximately 95% of the coding region, was analyzed to identify the amino acid variants
carried by the antibiotic producer strain.
Site-directed mutagenesis. Mutations in the E. coli rpsL gene were obtained using the
QuikChange XL kit (Stratagene) and, as the template for the PCR, the plasmid vector pET11a carrying
the coding sequence of S12, derived from E. coli MC4100 (rpsL150 [Strr]). The DNA sequences of the
oligonucleotide primers used to introduce codon variants are indicated in Table 1. E. coli DH5 cells
were transformed with the mutagenized plasmids, and Sanger DNA sequencing confirmed the
presence of mutated nucleotides.
Preparation of E. coli and Streptomyces S30 cell extracts. E. coli MRE600 cells were grown at 37°C
in LB medium until they reached mid-log phase, while Streptomyces cells were grown at 28°C in T1
medium for 45 h. Both cell types were disrupted by grinding with precooled alumina in a chilled mortar
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and processed following a previously described protocol (45). Both S30 extracts were extensively
dialyzed against a buffer containing 10 mM Tris-HCl (pH 7.7), 10 mM Mg acetate, 60 mM NH4Cl, and
0.5 mM dithiothreitol (DTT) and stored in small aliquots at –80°C.
Isolation of ribosomes and ribosomal subunits. The crude extract S30 was subjected to ultracen-
trifugation at 100,000 g for 17 h at 4°C. The supernatant, called S100, was stored at –80°C, while the
pellet, consisting of 70S ribosomes, was resuspended and split in two aliquots, one for in vitro assays and
one for preparation of 30S and 50S ribosomal subunits. 70S ribosomes were dissociated into subunits at
1 mM Mg2 concentration by ultracentrifugation at 25,000 rpm for 17h at 4°C in a swing bucket rotor
(SW28), on a 10% to 30% sucrose density gradient (45).
In vitro translation assays. Cell-free systems programmed with either poly(U) or 027 model mRNA
were used to investigate the effect of dityromycin on the bacterial translational apparatus. Translation
activity tests were performed using either S30 extracts or S100 extracts and 70S ribosomes, or criss-
crossed combinations of E. coli and Streptomyces sp. S100 extracts and 70S ribosomes (46).
Ribosome pulldown assay. The binding of dityromycin to either Streptomyces or E. coli 30S
ribosomal subunits was monitored by an ultracentrifugation-based assay. Increasing concentrations of
30S subunits were incubated for 10 min at room temperature with a fixed amount of antibiotic (1 M)
in 90 l of a solution consisting of 10 mM Tris-HCl (pH 7.7), 10 mM Mg acetate, 60 mM NH4Cl, and 0.5 mM
DTT. After ultracentrifugation in a S-100 AT-3 rotor at 100,000 rpm for 1 h at 4°C, aliquots of 20 l of the
supernatant were removed and tested in poly(U)-dependent in vitro translation assays.
Determination of MIC. To verify the incorporation of S12 mutants in E. coli ribosomes, a MIC plate
(5 rows  12 wells) was set up with increasing concentrations of streptomycin, ranging from 0.0 g/l
to 512.0 g/l. Each well of the plate contained 190 l of E. coli BL21(DE3)/pLysS cell culture. The plate
rows contained the following: (i) no-plasmid control, (ii) pET11a expression vector with rpsL150, (iii)
mutant V32/T32, (iv) mutant R55/K55, and (v) mutant V78/I78.
A MIC plate (4 rows  12 wells) with the four tester strains and a gradient of dityromycin (from
0.0 g/l to 400 g/l) was used to estimate the ability of the mutant proteins to counteract the
presence of the antibiotic. Further details are provided in the legend to Fig. 4.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00554-19.
FIG S1, JPG file, 2.2 MB.
FIG S2, TIF file, 2.6 MB.
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